NWBO
What one share of Northwest Biotherapeutics holds
Pharmaceutical Preparations
We are a biotechnology company focused on developing personalized immune therapies for cancer. We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer.
Northwest Biotherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.02 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.03 |
| Cash and investments | $0.00 |
| Debt | $0.01 |
| Book value | −$0.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.01 | −$0.77 | — | −$0.50 | — | −$0.17 |
| 2017 | $0.00 | −$0.31 | — | −$0.15 | — | −$0.20 |
| 2018 | $0.00 | −$0.12 | — | −$0.08 | — | −$0.09 |
| 2019 | $0.00 | −$0.04 | $0.00 | −$0.06 | — | −$0.07 |
| 2020 | $0.00 | −$0.73 | — | −$0.04 | — | −$0.44 |
| 2021 | $0.00 | −$0.06 | — | −$0.04 | — | −$0.13 |
| 2022 | $0.00 | −$0.10 | — | −$0.05 | — | −$0.12 |
| 2023 | $0.00 | −$0.06 | — | −$0.05 | — | −$0.06 |
| 2024 | $0.00 | −$0.07 | $0.00 | −$0.05 | — | −$0.07 |
| 2025 | $0.00 | −$0.04 | $0.00 | −$0.03 | — | −$0.04 |